In summary, we demonstrate that METTL3-mediated m6A modification of SCAP rewires cholesterol metabolism to impair CD8+ T cell antitumor response, thereby promoting NAFLD-HCC growth. Here, METTL3 is linked to metabolic dysfunction-associated steatotic liver disease.